-
My Account
In App
My Account
BSE Live
Apr 01, 16:00Prev. Close
859.90
Open Price
814.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 01, 15:59Prev. Close
859.80
Open Price
814.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
859.80 (9924)
| Cash Flow of Ranbaxy Laboratories (in Rs. Cr.) | Mar 14 | Dec 12 | Dec 11 | |
| 15 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | -848.43 | -164.28 | -3,048.67 | |
| Net CashFlow From Operating Activities | -1,217.10 | 641.24 | 128.38 | |
| Net Cash Used In Investing Activities | 922.04 | -1,670.89 | 1,765.14 | |
| Net Cash Used From Financing Activities | 717.28 | 314.55 | -1,275.14 | |
| Foreign Exchange Gains / Losses | -0.86 | 0.48 | 0.98 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 421.36 | -714.62 | 619.36 | |
| Cash And Cash Equivalents Begin of Year | 66.57 | 781.19 | 161.83 | |
| Cash And Cash Equivalents End Of Year | 487.93 | 66.57 | 781.19 |
04.05.2020
Book review: ‘Bottle of Lies’ explores Ranbaxy and the unethical underbelly of Indian pharma
01.08.2019
ED raids premises of former Ranbaxy group promoters under PMLA
20.12.2016
Withdraw nod for 28 drug applications of Ranbaxy: Sun Pharma
07.03.2016
Pharma crusader Thakur takes India's drug regulators to court
